Sector: Healthcare | Industry: Medical Equipment, Supplies & Distribution |
See Regulatory Filings on SEC |
Company Contact | |
Address: | BUILDING 1, SUITE 100, 41 SEYON STREET WALTHAM MA 02453 |
Tel: | N/A |
Website: | https://www.repligen.com |
IR: | See website |
Key People | ||
Olivier Loeillot President, Chief Commercial Officer | Tony John Hunt Chief Executive Officer, Director | Jason K. Garland Chief Financial Officer |
James R. Bylund Chief Operating Officer | Christine Gebski Senior Vice President of Filtration and Chromatography | Ralf Kuriyel Senior Vice President - Research and Development |
Business Overview |
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. The Company's bioprocessing business consists of four main franchises: filtration (including fluid management); chromatography; process analytics, and proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. The Company's chromatography franchise includes a number of products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. The Company's TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. |
Financial Overview |
For the fiscal year ended 31 December 2023, Repligen Corp revenues decreased 20% to $638.8M. Net income decreased 78% to $41.6M. Revenues reflect Product revenue - Filtration products segment decrease of 30% to $347.8M, Product revenue - Protein products segment decrease of 9% to $103.5M, North America segment decrease of 18% to $281.1M, Europe segment decrease of 20% to $236.3M. |
Employees: | 1,783 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $8,598M as of Dec 31, 2023 |
Annual revenue (TTM): | $638.76M as of Dec 31, 2023 |
EBITDA (TTM): | $160.72M as of Dec 31, 2023 |
Net annual income (TTM): | $41.58M as of Dec 31, 2023 |
Free cash flow (TTM): | $74.93M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 55,838,548 as of Mar 18, 2024 |
Index Membership: | S&P 400 Mid Cap |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |